Abstract:Eighty‐one low‐risk first cadaveric renal allograft (CD1) recipients have been studied to evaluate an immunosuppressive regime consisting of azathioprine (AZA) [2 mg/kg initially] and cyclosporine A (CSA) [8 mg/kg initially] but without prednisolone in the first instance. All patients were transfused and had less than 50% panel‐reactive antibodies in both peak and current sera. The dose of CSA was tapered to 4 mg/kg at 10 weeks and the AZA to 1 mg/kg at 17 wk. Rejection episodes were treated with 3 × 1 g i.v. boluses of methylprednisolone. After the second episode, or if the first episode was severe, patients were commenced on oral prednisolone at a dose of 30 mg/day reducing to a baseline of 10 mg 12 wk later. Steroid‐unresponsive or histologically severe rejection was treated with OKT3 or ATG. Median follow‐up to the end of March 1989 was 15.5 months (range 3‐33). The 12‐month actuarial patient and graft survivals were 97% and 87% respectively. Four patients died with functioning grafts at 2, 7, and 17 months of infection (3) and at 13 months of myocardial infarction (1). Three grafts were lost to rejection at 4, 7 and 9 months. Four grafts experienced extensive intragraft thromboses in the 1st wk, leading to graft failure in 2, and 1 graft developed major vessel thrombosis at 5 months. Thirty‐eight patients required post‐operative dialysis. Of these, 2 never functioned, 3 diuresed without CSA reduction, 17 functioned after a 50% reduction and 16 functioned after cessation of CSA. Excluding 2 grafts which failed in the first 2 d because of vascular complications, 20 patients (25%) never experienced rejection, 31 (39%) developed their first rejection in the 1st wk, 18 (23%) in wk 2‐4 and 10 (13%) after the 1st month. Fifteen patients required OKT3 or ATG for severe rejection. Fifty‐one patients (65%) received courses of oral steroids of longer than 4 wk, 35 for rejection, 10 after cessation of CSA for toxicity, and 3 after cessation or reduction of AZA for toxicity. Thirteen (37%) of the patients on prednisolone for rejection have had it stopped at between 7 and 25 months without further rejection. Of the 65 patients with functioning grafts who have been followed for more than 6 months, 38 (59%) are taking CSA and AZA alone and 26 (40%) are taking prednisolone either with AZA and CSA (15), with AZA alone (8) or with CSA alone (3). One patient is taking only CSA. There were 30 infections in 28 patients. The most significant of these were 14 CMV (5 associated with OKT3), 1 Torula, 2 wound infection, 3 bacterial septicemia, 1 fungal septicemia, 2 bacterial pneumonia and several episodes of ascending cholangitis in 1 patient. This experience shows that 35% of low‐risk CD1 recipients can be successfully treated with CSA and AZA without prednisolone and that, after 6 months, maintenance immunosuppression can be achieved without long‐term steroids in more than half of the group.

Cholestasis after azathioprine administration in renal transplant recipients: Report of 7 cases

Analysis of Adverse Drug Reactions of Azathioprine in the Treatment of Patients with Inflammatory Bowel Disease

Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report

Azathioprine hepatotoxicity and the protective effect of liquorice and glycyrrhizic acid.

P303 Hyperbilirubinemia Can Be Induced with Azathioprin Treatment in Patients with Inflammatory Bowel Disease: a Hospital-Based Cohort Study

Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.

P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis

A case report of reversible intracranial lesions after long-term Azathioprine therapy in an autoimmune hepatitis patient

Safety issues in the management of autoimmune hepatitis

A case of severe bone-marrow suppression due to azathioprine in a patient of kidney transplant

Experience with cyclosporine A and azathioprine double therapy in low‐risk recipients of first cadaveric renal allografts

Steroid therapy for a case of severe drug-induced cholestasis

Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin

Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report

Severe Liver Injury after Treatment with the Leukotriene Receptor Antagonist Zafirlukast

Cardiac and vascular abnormalities in renal transplant patients: differential effects of cyclosporin and azathioprine

Fk506 Caused 2 Cases Liver Damage after Kidney Transplantation and Review of Literature

Toxicity versus rejection ‐ Or why conversions between cyclosporine A and FK506 were performed after liver transplantation

Post-transplant manifestation of ankylosing spondylitis: a case report and review of literature

Successful treatment of prolonged cholestasis following hepatitis A infection in a child with oral steroid therapy

Azathioprine therapy induces selective NK cell depletion and IFN-γ deficiency predisposing to herpesvirus reactivation